Introduction
============

Glucose homeostasis is an essential metabolic process of mammalian organisms based upon a series of biochemical reactions. Glucose homeostasis can be divided into three phases: glucose absorption and organ distribution, glycolysis and glycogen synthesis, glycogenolysis and gluconeogenesis.

The liver is an organ that performs essential functions for glucose homeostasis. Portal vein is the functional vascular system of the liver. Seventy to eighty percent of the blood supply comes from the portal vein, which is enriched with nutrients, such as sugars, amino acids, vitamins, essential fatty acids and so on. When flowing through the sinusoid, the nutrients are absorbed and further "processed" by hepatocytes and a part of them flows back into the bloodstream for body energy supply with the remainder stored for use when needed.[@b1-dddt-12-121]

Imbalanced glucose homeostasis in the liver causes metabolic syndromes (MSs), which are a combination of disorders including high blood pressure, high serum triglyceride level, impaired fasting glucose or insulin resistance, and so on.[@b2-dddt-12-121] MS is a high-risk factor for coronary heart disease, diabetes, stroke, hypertension and chronic liver diseases.[@b3-dddt-12-121]

Based on the promotion of weight loss and physical exercise, lifestyle modification is an effective method of improving mild and moderate MSs induced by imbalanced glucose homeostasis.[@b4-dddt-12-121] For example, high dietary cholesterol together with high dietary fat can interact synergistically to develop hepatic steatosis, a reversible condition wherein a large amount of lipid droplets accumulate in liver cells, as well as its associated metabolic abnormalities.[@b5-dddt-12-121] Moreover, chronic intake of Western-style diets, including fructose and/or fat, and alcoholic beverages also may induce hepatic damage, MSs and such accompanying diseases as nonalcoholic fatty liver disease, over time.[@b6-dddt-12-121],[@b7-dddt-12-121] However, some effective preventive approaches such as lifestyle changes, exercise, and adherence to Mediterranean diet can reduce the specific risk factors.[@b8-dddt-12-121],[@b9-dddt-12-121] Some target-based drugs have been developed for MS treatment, such as insulin sensitizing agent (metformin), peroxisome proliferator-activated receptor agonists (fibrates) and α-glucosidase inhibitor (acarbose), which have produced significant effects in clinical trials.

From the molecular biology perspective, MS is characterized by an imbalance of the glucose homeostasis network with multiple pathogenic mechanisms and is not likely to result from one single target defect. Multitarget drugs have raised considerable interest regarding the regulation of imbalanced glucose homeostasis. Recently, a number of publications have indicated that it is necessary to expand drug development toward the multitarget approach for complex pathologies of systemic diseases.[@b10-dddt-12-121],[@b11-dddt-12-121] Compared with single-target medication, some multitarget approaches can synergistically act on multiple targets of diseases and thus may be more effective at controlling complex disease systems like MSs.

Some compounds isolated from natural medicines have been reported as regulators of glucose homeostasis with a multitarget manner. For example, 1-deoxynojirimycin, an alkaloid from mulberry leaves (*Morus alba* L., Moraceae), has been found to be an α-glucosidase inhibitor with adiponectin enhancement,[@b12-dddt-12-121] β-oxidation activation and lipid accumulation inhibitory effects.[@b13-dddt-12-121],[@b14-dddt-12-121] Berberin, an alkaloid isolated from Rhizoma coptidis (*Coptis chinensis* Franch., Ranunculaceae), has shown regulating effects on abnormal lipid and glucose metabolism. The mechanism includes improving insulin resistance,[@b15-dddt-12-121] promoting insulin secretion,[@b16-dddt-12-121] inhibiting gluconeogenesis in the liver,[@b17-dddt-12-121] stimulating glycolysis in peripheral tissue cells,[@b18-dddt-12-121] and modulating gut microbiota.[@b19-dddt-12-121] Curcumin, a phenolic compound isolated from *Curcuma longa*, has shown potential effects on glucose homeostasis through modulating oxidation stress status and inflammation cascades in a high-fat-diet-induced MS model,[@b20-dddt-12-121],[@b21-dddt-12-121] as well as stimulating expression of nuclear factor κB (inflammation-related transcription factor), TNF-α, leptin and catalase.

In this review, we provide a summary of known roles on liver glucose homeostasis in human physiologic and pathophysiologic processes, summarize the potential bioactive compounds from natural products with medicinal value, and also focus on polypharmacologic and multitarget natural products related to various signaling pathways in hepatic glucose metabolism.

Hepatic glucose utilization in normal and metabolically disturbed states
========================================================================

The liver contributes to more than one third of the dietary glucose absorption after a meal. It maintains the glycemic control in a normal physiology by rapid clearance of glucose circulating in the blood through uptake, glycolysis and glycogen synthesis. However, in a state of metabolic disturbance, several major enzymes are abnormally expressed in the liver, and focusing on these targets is of great therapeutic significance in drug development.

Hepatocyte glucose uptake
-------------------------

### Hepatocyte glucose uptake in normal state

Hepatic glucose uptake in normal state is mediated by three major factors, including the insulin concentration in the hepatic sinusoid, the signaling produced by the arterial-portal glucose gradient (portal signaling) and the distribution of the intraportally infused glucose to the liver (hepatic glucose load). In hepatocytes, the glucose transporter type 2 (solute carrier family 2, member A2, SLC2A2 or GLUT2) contributes predominantly to the human hepatic glucose uptake. The expression and activity of GLUT2 is transcriptionally regulated by peroxisome proliferator-activated receptor-γ (PPAR-γ)[@b22-dddt-12-121] as well as hepatocyte nuclear factor (HNF)-1α, HNF-3β and HNF-4α,[@b23-dddt-12-121]--[@b25-dddt-12-121] but is independent of insulin signaling. Moreover, glucokinase (GK) also has a close relationship with hepatic glucose uptake. In basal state (with a glucose concentration of about 5.5 mmol/L), GK exists in the nucleus and is combined with glucose kinase regulatory protein (GKRP). When hepatocytes are exposed in hyperglycemia (with a glucose concentration of about 10--30 mmol/L), GK is released and translocated into the cytoplasm to promote the glucose uptake and utilization ([Figure 1](#f1-dddt-12-121){ref-type="fig"}).

### Hepatocyte glucose uptake in metabolically disturbed state

Hepatic glucose uptake is impaired in MS patients, which is one of the reasons for postprandial hyperglycemia and may be induced by the impairment of some of the above regulation factors. In human subjects, the protein expression of GLUT2 is much higher in obese than that in lean subjects; however, obese patients with non-insulin-dependent diabetes do not show a further upregulation compared to obese controls in spite of their hyperglycemic status.[@b26-dddt-12-121] The possible reason is that GLUT2 is a bidirectional transporter that also contributes to the transportation of glucose out of hepatocytes. While hepatic glucose uptake is also associated with many other factors including GK as the decrease of GK translocation in diabetic state would reduce the glucose uptake and therefore weaken the glucose disposal ability of the liver.

### GLUT2 inhibitors for glycemic control

A number of studies suggest that overexpression of hepatic GLUT2 is found in many diabetic animals or cells.[@b27-dddt-12-121]--[@b31-dddt-12-121] Using these models, some PPAR-γ agonists, such as rosiglitazone and thiazolidinediones, have been reported to stimulate the release and synthesis of insulin in pancreatic β-cells through the upregulation of *GLUT-2* and *GK* gene expressions, and they can also directly activate hepatic GK expression in primary hepatocytes, thereby improving glucose homeostasis in MS patients.

In recent years, some crude plant extracts have also been reported to reverse overexpression of GLUT2 or suppress its translocation from the cytoplasm to the plasma membrane in cases of MSs or hepatic steatosis. The representative plants include *Ficus deltoidea* (Moraceae) leaves,[@b32-dddt-12-121] *Ganoderma lucidum*,[@b33-dddt-12-121] *Psidium guajava* leaves,[@b34-dddt-12-121] *Symplocos cochinchinensis*[@b35-dddt-12-121] and *Urtica dioica* (stinging nettle) leaves.[@b30-dddt-12-121]

In addition to these crude plant extracts, more and more pure compounds have been found to produce similar effects, such as resveratrol,[@b36-dddt-12-121],[@b37-dddt-12-121] ankaflavin,[@b38-dddt-12-121] curcumin,[@b39-dddt-12-121] ferulic acid[@b40-dddt-12-121] and caffeic acid phenethyl estertaurine.[@b41-dddt-12-121] For example, ferulic acid, a phenolic acid isolated from *Ferula assafoetida*, can restore the elevated gluconeogenesis to a normal level in Wistar rats with high-fat diet,[@b40-dddt-12-121] the mechanism of which involves downregulating hepatic GLUT2 expression and SREBP-1c, HNF-1α and HNF-3β transcription factors.

Hepatic glycolysis
------------------

### Hepatic glycolysis in normal state

Once taken up into hepatocytes, glucose is first phosphorylated by GK to yield glucose-6-phosphate. GK accounts for 95% of glucose phosphorylation activity and is transcriptionally controlled by insulin and glucagon so that insulin increases the mRNA expression and activity of GK, whereas glucagon has the opposite effect.[@b42-dddt-12-121] GKRP acts as a competitive inhibitor of glucose, binding to GK and sequestering the enzyme to the nucleus.[@b43-dddt-12-121]

Two other key rate-limiting enzymes in the liver of the 10-step glycolysis are phosphofructokinase-1 and liver-type pyruvate kinase M2. The former catalyzes the metabolically irreversible step that essentially converts fructose 6-bisphosphate into fructose 1,6-bisphosphate, and the latter catalyzes the final step of the process that converts phosphoenolpyruvate (PEP) into pyruvate. Both of the two kinases can be regulated by insulin, glucagon and epinephrine via protein kinase A (PKA) and the phosphoinositide-3-kinase (PI3K)/Akt pathway in the presence of glucose.

With food intake, in addition to the acute regulation of the above enzymes, glycolysis is also regulated by sterol regulatory element-binding protein 1c (SREBP-1c) and carbohydrate response element binding protein (ChREBP). Recent studies have indicated the involvement of various kinases in the control of SREBP-1c and ChREBP activities. PKA is shown to mediate the negative regulatory effect of glucagon on SREBP-1.[@b44-dddt-12-121] AMP-activated protein kinase (AMPK) blocks proteolysis and nuclear localization of SREBP-1c,[@b45-dddt-12-121] while AMPK-related salt-inducible kinase 1 (SIK1) directly reduces its transcriptional activity.[@b46-dddt-12-121] In addition, liver X receptor α (LXRα) and C/EBP-β also contribute to the transcription of SREBP-1c.[@b47-dddt-12-121] Likely, for ChREBP, PKA is critical for its cellular localization[@b48-dddt-12-121] and AMPK is important for its DNA binding ability ([Figure 2](#f2-dddt-12-121){ref-type="fig"}).[@b49-dddt-12-121]

### Hepatic glycolysis in metabolically disturbed state

In patients with hepatopathy, activities of enzymes involved in glycolysis and the Krebs cycle are significantly decreased, which results in a decline of regulatory functions. If insulin resistance and insulin secretion or metabolism dysfunction also coexist, it is more likely to develop into hepatic diabetes.[@b50-dddt-12-121] In diabetic state, the hepatic deactivation effect on insulin agonist, glucagon and catecholamines is decreased. And, with the reduction of the insulin/glucagon ratio, hepatic glycolysis is difficult to trigger, causing an obstacle for glucose utilization. In addition, although total GK is probably decreased in the pancreas, the β-cell GK has been strongly proved to be functional. However, the hepatic GK expression is quite different and may be greatly reduced because of its insulin-dependent manner.[@b51-dddt-12-121],[@b52-dddt-12-121]

### Liver-specific GK activators for glycemic control

Activation of GK has potential effects both in the pancreas and in the liver, which would have a significant effect on circulating glucose levels in the diabetic state. However, targeting the pancreas would ultimately result in a worsening of the diabetic state because it would not only result in hypoglycemia but also lead to more profound β-cell failure. For this reason, a liver-selective GK activator is a safer and more effective antidiabetic agent compared to the pancreas-targeted one.

In the past few years, a number of small-molecule synthetic GK activators have been found,[@b53-dddt-12-121] and Phase II trials of some GK activator drugs are now underway, such as for AZD-1656, AZD-6379, TTP-399, PF-04937319, GKM-001 and GK1--399. However, some of them have been identified as having poor druggability because of their low hepatic selectivity and unexpected side effects.

Many crude extracts of natural plants have been proved to have mild yet compelling effects on enhancing hepatic GK activity and restoring liver glycogen, such as *Polygonatum kingianum*,[@b54-dddt-12-121] *Ventilago maderaspatana*,[@b55-dddt-12-121] *Ulva fasciata*,[@b56-dddt-12-121] *Phyllanthus amarus*[@b57-dddt-12-121] as well as *Achyranthes aspera*[@b58-dddt-12-121] and *Artemisia sphaerocephala*.[@b59-dddt-12-121] For example, total saponins from *Polygonatum kingianum* were found to control blood glucose in streptozotocin-induced diabetic rats via upregulating the expression of GLUT4, PPAR-γ, AMPK and hepatic GK as well as downregulating the expression of G6P to promote not only glycogenesis but also glucose utilization. Nonetheless, findings on effective pure natural compounds are so far limited. Known effective compounds include tatanans A-C from *Acorus tatarinowii* plants[@b60-dddt-12-121] and four bioactive ingredients in mulberries (1-deoxynojrimycin, resveratrol, cyanidin-3-glucoside and cyanidin-3-rutinoside).[@b61-dddt-12-121] Thus, natural products as promising entities for GK activators have immense potential to be investigated in the future.

Hepatic glycogen synthesis
--------------------------

### Hepatic glycogen synthesis in normal state

In the abundant glucose condition, the redundant glucose-6-phosphate is converted into uridine diphosphate glucose and then glycogen synthesis starts with the catalysis of glycogen synthase (GYS). GYS is phosphorylated and thus inactivated in a very complex and insufficiently characterized manner involving multiple phosphorylation sites and by several kinases including AMPK, PKA and glycogen synthase kinase 3 (GSK-3). GSK-3 is a downstream target of PI3K/Akt and thus insulin signaling cascades. In addition, GYS can also be dephosphorylated and subsequently activated by protein phosphatase-1, which is considered to be involved in the mechanism of insulin-enhanced glycogen synthesis in the liver ([Figure 3](#f3-dddt-12-121){ref-type="fig"}).

### Hepatic glycogen synthesis in metabolically disturbed state

In healthy subjects, about 50% of the glucose is stored as glycogen after a meal, whereas in patients with impaired glucose tolerance, the ability to store glucose is reduced.[@b62-dddt-12-121] As the hepatic capacity to store glycogen is limited, the excess dietary glucose is used to synthesize fat by hepatic de novo lipogenesis in the carbohydrate overfeeding condition.[@b63-dddt-12-121] The risk of hepatic lipid accumulation is thus increased. Moreover, in the development of MSs, dysregulation of GSK-3 has been reported to be involved and the two isoforms, GSK-3α and GSK-3β, play distinct and tissue-specific roles in this pathologic process.[@b64-dddt-12-121] In nonalcoholic steatohepatitis subjects or diet-induced obesity and MS rat models, the expression of the insulin receptor and insulin receptor substrate-1/2 (IRS-1/2) is also markedly reduced, which subsequently induces the impairment of insulin signaling and inhibition of glycogen synthesis.[@b65-dddt-12-121],[@b66-dddt-12-121]

### GSK-3 inhibitors for glycemic control

Substantial evidence has demonstrated the linkage between GSK-3 and the development of MSs.[@b62-dddt-12-121],[@b67-dddt-12-121],[@b68-dddt-12-121] A strategy of GSK-3 inhibition for the treatment of MSs should hence be designed. Although dysregulation of GSK-3 is also involved in many other diseases including Alzheimer's disease, bipolar disorder and cancer, many chemical GSK-3 inhibitors have been described and verified as potent agents in enhancing the hepatic GS activity.[@b69-dddt-12-121]

To our knowledge, in natural products, direct GSK-3 inhibitors have been rarely reported, but a number of natural products can indirectly promote glycogen synthesis through PI3K/Akt-mediated GSK-3 phosphorylation. These compounds include epigallocatechin-3-gallate (EGCG) from green tea,[@b70-dddt-12-121] nigelladines A--C from the seeds of *Nigella glandulifera*,[@b71-dddt-12-121] as well as ursolic acid and luteolin-7-glucoside present in many plants particularly abundant in the Salvia species.[@b72-dddt-12-121]

Hepatic production in normal and metabolically disturbed states
===============================================================

When nutrients become scarce, the liver releases glucose into the bloodstream by two pathways, glycogen breakdown (glycogenolysis) and glucose de novo synthesis (gluconeogenesis). High fasting glucose levels are warning signs of MSs, one of the causes being overproduction of hepatic glucose. Some listed hypoglycemic drugs, such as metformin, glyburide and pioglitazone, inhibit hepatic glucose overproduction. In addition, many crude plant extracts and natural products also exhibit similar effects.[@b73-dddt-12-121]--[@b75-dddt-12-121]

Hepatic glycogenolysis and gluconeogenesis in normal state
----------------------------------------------------------

During the period of short-term fasting, glycogenolysis is the predominant glucose source and glycogen polymer degradation is catalyzed by glycogen phosphorylase (GP) through unfastening the α-1,4-glycosidic bonds and liberating glucose 1-phosphate, which can be converted into glucose 6-phosphate by phosphoglucomutase. Glucose 6-phosphate is then further converted into glucose by glucose 6-phosphatase (G6Pase) or incorporated into glycolysis depending on the energy status. GP is regulated via phosphorylation by PKA, which can be inhibited by insulin and gene expression of G6Pase that is induced by both hyperglycemia and by insulin deficiency.

Following prolonged periods of fasting, glycogen reserve is gradually consumed and gluconeogenesis becomes the predominant source. Some precursors, such as pyruvate, lactate, alanine and glycerol, are used for hepatic glucose de novo synthesis ([Figure 4](#f4-dddt-12-121){ref-type="fig"}). Gluconeogenesis can be briefly described as a two-stage process: first, the precursors (excluding glycerol) are converted into oxaloacetate catalyzed by pyruvate carboxylase (PC) and then into PEP by phosphoenolpyruvate carboxykinase; secondly, PEP is converted into fructose 6-phosphate catalyzed by fructose 1,6-bisphosphatase (FBPase) and further generates glucose catalyzed by G6Pase. The chronic activation of gluconeogenesis is controlled by several major transcriptional factors including cAMP responsive element binding protein (CREB) and CREB-regulated transcription coactivator (TORC)-2, peroxisome proliferator-activated receptor gamma co-activator 1 alpha and forkhead box O1 ([Figure 5](#f5-dddt-12-121){ref-type="fig"}).

Hepatic glycogenolysis and gluconeogenesis in metabolically disturbed state
---------------------------------------------------------------------------

In the diabetic state, the liver becomes resistant to insulin and the hepatic glucose production is consequently increased in MS patients, which contributes to the postprandial hyperglycemia. The changes in expressions of proteins involved in glucose metabolism, resulting from chronic hyperglycemia, would further aggravate the metabolic imbalance, which is described as "glucose toxicity". For example, elevated hepatic GP and G6Pase activity occurs in hyperglycemic conditions, which are responsible for the impaired glycogen synthesis. Hyperglycemia promotes the elevation of GP and G6Pase, which in turn leads to further increases in glucose production. Moreover, G6Pase catalyzes the terminal steps in both the processes. However, levels of the G6Pase catalytic protein, whose active site locates at the luminal side of the endoplasmic reticulum, and the expressions of T~1~-translocase, a specific transporter that mediates the entry of G6Pase into the luminal compartment, T~2~-translocase, which mediates the export of inorganic phosphate back to the cytosol, and T~3~-translocase, which mediates the export of glucose back to the cytosol, have been shown to be dysregulated in diabetes.[@b76-dddt-12-121]--[@b78-dddt-12-121]

GP inhibitors for glycemic control
----------------------------------

Inhibiting overproduction of hepatic glucose is one of the major mechanisms of many listed hypoglycemic drugs, such as metformin, glyburide and pioglitazone. However, they are not direct inhibitors of hepatic GP. Although a direct GP inhibitor, nitrogen heterindoleamide derivative PSN-357, has been tested in Phase II study,[@b143-dddt-12-121] which found that it is difficult to develop this drug into a liver selective type. In fact, inhibiting the activity of GP to prevent unwanted glycogenolysis is an effective way for glycemic control.

GP has at least five different ligand-binding sites that might prevent glycogenolysis under high glucose levels, and so far dozens of natural product inhibitors have been identified. Some iminosugars that bind to the catalytic site of GP, such as 1,4-dideoxy-1,4-imino-D-arabinitol, as well as isofagomine and its derivative have been reported as potent inhibitors of liver GP and of basal and glucagon-stimulated glycogenolysis.[@b79-dddt-12-121],[@b80-dddt-12-121] Flavonoids (including quercetin, chrysin and flavopiridol), indirubins and catechin gallates that bind to the inhibitor site[@b81-dddt-12-121]--[@b83-dddt-12-121] as well as pentacyclic triterpenes that bind to the allosteric site[@b84-dddt-12-121] have been revealed as inhibitors of GP at micromolar levels. Consequently, binding to the allosteric site of GP also may be one of the possible antidiabetic mechanisms of certain active plants rich in flavonoids.

G6Pase inhibitors for glycemic control
--------------------------------------

It is possible that pharmacologic inhibitors targeting the G6Pase will likely inhibit other phosphatases, thus leading to undesirable consequences. However, G6Pase translocases are more rational targets for pharmacologic intervention because they are structurally distinct and catalyze the slow step of glucose production.

The known G6Pase inhibitors can be placed into two categories: catalytic protein inhibitors and inhibitors of T~1~-, T~2~- and T~3~-translocase. Among these inhibitors, some natural products such as chlorogenic acid[@b85-dddt-12-121] exhibited high inhibitory affinities to the translocase sites, and is a secondary metabolite of many plants, phloretin and phlorizin,[@b86-dddt-12-121] which are the principal phenolic components of apple trees, flavonoids from *Bauhinia megalandra* leaves,[@b87-dddt-12-121] as well as many products of fungi or bacteria,[@b88-dddt-12-121] including kodaistatin, anthraquinones, mumbaistatin and thielavins. In addition, it is reported that extracts of some plants also inhibit the transcriptional expression or activity of G6Pase, and include mulberry branch bark extract,[@b89-dddt-12-121] aqueous extract of *Clitocybe nuda*[@b90-dddt-12-121] and methanolic extract of *Ventilago maderaspatana*.[@b55-dddt-12-121]

Multitarget approach of natural products used to act on hepatic glucose homeostasis
===================================================================================

Dysregulation of hepatic glucose metabolism is comprised of complex mechanisms, and according to the abnormally changed enzymes in the metabolically disturbed state ([Table 1](#t1-dddt-12-121){ref-type="table"}), a series of pertinent drugs or predrugs have been discovered or developed. Natural products have been widely accepted to be the source of most active ingredients in many medicines. In the recent decade, substantial efforts have been made to discover novel compounds, which can be applied therapeutically in the treatment of MSs. A number of natural pure compounds and crude extracts have been made available for glycemic control with different mechanisms of action, an important proportion of which are in the multitarget approach.

Several decades ago, drug development was only focused on a limited number of crucial targets for diseases. However, with the increasing concern of the drawbacks of single-target drugs, such as single regulation linkage, low clinical efficacy, high risks of side effects, and strong drug resistance, "combination therapy" emerged, though the shortcomings mentioned above were not truly solved. In contrast, multitarget natural products are now becoming common and exhibit distinct advantages, especially in the treatment of complex and chronic diseases like MSs. Some of the most studied potential antidiabetic natural products with privileged structures are quercetin, resveratrol, EGCG, curcumin, berberin and salicylat. For example, berberin is an antimicrobial isoquinoline plant alkaloid present in many plants such as *Berberis vulgaris*, *C. chinensis* and *Berberis aristata*, and it also possesses some other pharmacologic properties including antitumoral, glucose- and cholesterol-lowering as well as immune-modulatory activities. With regard to its hypoglycemic effect, the direct molecular targets of berberin are AMPK,[@b18-dddt-12-121] PPARs,[@b91-dddt-12-121] ERK,[@b92-dddt-12-121] PKC[@b93-dddt-12-121] and glucagon-like peptide-1 (GLP-1)[@b94-dddt-12-121] ([Table 2](#t2-dddt-12-121){ref-type="table"}). The downstream targets that are directly involved in glucose metabolism are subsequently regulated to achieve the glycemic control. In addition, the regulation of berberin is a multitissue process involving the liver, muscle, adipose tissue, pancreas and small intestine. Through the multiple regulation linkage, berberin exhibits stable and safe effects on experimental and clinical glycemic control.

Discussion
==========

The liver plays an important role in the regulation of glucose metabolism. Glucose homeostasis disorder is a risk factor for diabetes, heart disease and stroke. Several medications are used to regulate glucose homeostasis. For example, metformin, which is commonly used to improve fasting hepatic insulin sensitivity and reduce hepatic glucose production. Glyburide, a kind of sulfonylurea, decreases glucose production and enhances insulin action in the liver.[@b128-dddt-12-121] Pioglitazone, a kind of thiazolidinedione, improves hepatic insulin sensitivity and reduces hepatic glucose production.

Recently, current medication treatments appear to be ineffective or contraindicated in growing numbers of patients, and as a result, difficult-to-treat diseases require alternative therapies. According to pathophysiologic research results, the pharmaceutical industry has promoted the development of innovative therapies on novel targets involved in liver glucose metabolism. The GK activators, PF-04937319 and GKM-001, have been developed by Pfizer Inc. and Advinus Therapeutics Ltd., respectively. PSN-357, a GP inhibitor with a nitrogen heterindoleamide structure, has been developed by OSI Pharmaceuticals Inc. PTP1B inhibitor, ISIS-PTP-1BRx (Isis Pharmaceuticals Inc.) and TTP-814 (TransTech Pharma Inc.) have completed Phase II trials. Liver-specific GK activator, GSK-3 inhibitor, GP inhibitor, FBPase inhibitor, G6Pase inhibitor, PTP1B inhibitor and FFAR1 activator are becoming hotspots in target-based new drug development.

Lead compound from natural products is one of the most important resources for developing new drugs. Generally, natural products have less activity and nonselectivity compared with synthesized compounds. For example, in the discovery of GK activator, the half maximal effective concentration (EC~50~) of synthesized activator TMG-123 was \<1 µM,[@b129-dddt-12-121] while to our knowledge, the best EC~50~ of the natural product, mangiferin (a xanthone glucoside from the leaves of *Mangifera indica* and the root of *Anemarrhena asphodeloides*), was more than 100 µM.[@b130-dddt-12-121] In addition to GK activation activity, mangiferin has various other functions via diverse targets, such as antioxidant, antimicrobial, antidiabetic, antiallergic and anticancer,[@b131-dddt-12-121] which exhibits its nonselective characteristic feature.

The problem of less activity of natural products can be solved by chemical structural modification. In the early 20th century, researchers isolated a guanidine named galegine from *Galega officinalis* which belongs to the Fabaceae family, with weak antidiabetic activity. After structural modification, a series of biguanides were synthesized, and finally, metformin was developed as an "elixir" for clinical MS management.[@b132-dddt-12-121] Now, it has been proved that metaformin is a unique diabetes management drug with prevention of diabetic macrovascular complications.[@b133-dddt-12-121]

Nonselectivity of natural products is a weak point in target-based new drug development. However, it is an advantage point for multitarget disease treatment. As described in the introduction, MS is characterized by an imbalance of the glucose homeostasis network with multiple pathogenic mechanisms. Multitarget drugs have raised considerable interest regarding the regulation of imbalance of glucose homeostasis. Berberin, an alkaloid isolated from *C. chinensis* (Ranunculaceae), showed potential regulatory effect on MSs, and the mechanism was revealed to be partly related to AMPK, PI3K, AKT, TNF-α, NF-κB, GLP-1, GLUT4, PPAR-γ, and so on.[@b134-dddt-12-121] This phenomenon may be attributed to its planar structure of tricycle rings with a quaternary ammonium group, which is flexible enough to bind with ligands, but does not exhibit significant selectivity. With regard to its multitarget manner, berberine exhibited significant regulatory effects on glucose homeostasis.[@b135-dddt-12-121]

Multitarget drugs can be divided into two types, one-compound--multitarget and multicompound--multitarget. Generally, most compounds can interact with more than one target, including target-based synthesized compounds. This one-compound--multitarget characteristic is less beneficial for drug development; it sometimes leads to a loss of higher efficacy and an increase in the undesirable risks of toxicity and side effects. Multicompound--multitarget drugs are another direction of development methods for complex diseases. This strategy has been successfully used in MS clinical trials and achieved the goal of regulation.[@b136-dddt-12-121]

In management of MSs, the traditional Chinese medicine (TCM) is an excellent representative therapy in alternative and complementary medicines.[@b137-dddt-12-121] Fang Feng Tong Sheng San, a preparation composed of 18 medicinal plants, has been shown to exert antiobesity, antidiabetes and lipid-lowering activities[@b138-dddt-12-121] in clinical trials and laboratory experiments, and was used in China, Japan and Korea as an over-the-counter drug. Our previous study reported that Tangzhiqing formula, containing red peony root, mulberry leaf, lotus leaf, Danshen root and hawthorn leaf, upregulated PI3K, AKT, GYS and their phosphorylation, as well as GLUT4.[@b139-dddt-12-121] Jinqi formula, containing Coptidis Rhizoma, Astragali Rhadix and Lonicerae japonicae Flos, showed inhibitory effects on triglyceride accumulation in the treatment of diabetes and obesity, and the mechanism was confirmed at least in part via the stimulation of AMPK activity in a multitarget manner.[@b140-dddt-12-121]

Clinical evidence of TCM formulas provides an indication of multicompound--multitarget type drug development. At least, on the basis of further therapy mechanisms and active material research, the results can offer an appropriate combination of compounds and a rational dose proportion. On the other hand, the comparison of different TCM formulas for MSs will lead to an understanding of key targets working in the MS network, and the identification of new therapeutic targets.

One TCM formula contains many kinds of compounds. Drug--target network screening will yield an immense amount of data, which will require warehouse-scale computing and sophisticated algorithms.[@b141-dddt-12-121] Network pharmacology is a systematic biologic methodology for network analysis and drug design, which can illustrate the interactions between active compounds and multiple targets.[@b142-dddt-12-121] More new systematic technologies are potentially useful for studying the action mechanisms of traditional natural medicines to develop valuable multitarget lead compounds from natural products for structural optimization with proven preclinical and clinical evidence in MS treatment.

Oriental medicine is a system of health care based on improving overall body function, while Western medicine has achieved great successes in target therapy. Combining the clinically effective oriental multicompound--multitarget drugs with the achieved Western study methods, and focusing on the clinical effects for the development of new drugs for MSs will be an integrated way to achieve benefits for all humanity.
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![Regulation of hepatic glucose uptake.\
**Notes:** Glucose absorbed in the small intestine is transferred from blood into hepatocytes by GLUT2, which is transcriptionally regulated by hepatocyte nucleus factor PPAR-γ and HNFs. GK also contributes to the promotion of hepatic glucose uptake, which is competitively inhibited by binding with GKRP in the nucleus in basal state and is released and translocated into cytoplasm in hyperglycemic state. See the main text for more specific regulatory pathways.\
**Abbreviations:** GK, glucokinase; GKRP, glucose kinase regulatory protein; HNF, hepatocyte nuclear factor; PPAR, peroxisome proliferator-activated receptor; SREBP-1c, sterol regulatory element-binding protein 1c.](dddt-12-121Fig1){#f1-dddt-12-121}

![Regulation of hepatic glycolysis.\
**Notes:** The absorbed glucose undergoes the glycolysis process that is catalyzed by three major enzymes, GK, PFK-1 and PKM2, successively, to generate pyruvate. The last two kinases are regulated by hormones via PKA and Akt in the presence of glucose and transcriptionally regulated by SREBP-1c and ChREBP. See the main text for more specific regulatory pathways.\
**Abbreviations:** AMPK, AMP-activated protein kinase; cAMP, cyclic adenosine monophosphate; ChREBP, carbohydrate response element binding protein; GK, glucokinase; PFK-1, phosphofructokinase-1; PKA, protein kinase A; PKM2, pyruvate kinase M2; SREBP-1c, sterol regulatory element-binding protein 1c.](dddt-12-121Fig2){#f2-dddt-12-121}

![Regulation of hepatic glycogen synthesis.\
**Notes:** When glucose is abundant, glucose is stored in the form of glycogen catalyzed by GYS, which is mainly regulated by AMPK, PKA and PI3K/Akt pathways. See the main text for more specific regulatory pathways.\
**Abbreviations:** AMPK, AMP-activated protein kinase; GYS, glycogen synthase; PI3K, phosphoinositide-3-kinase; PKA, protein kinase A.](dddt-12-121Fig3){#f3-dddt-12-121}

![Regulation of hepatic glycogenolysis.\
**Notes:** Under fasting condition, hepatic glycogenolysis is enhanced via an increased concentration of glucagon and epinephrine. GP, phosphoglucomatase and G6Pase are critical in coordinating the fasting-mediated activation of glycogenolysis. The solid black line represents the pathway under fasting condition and the red dotted line the feeding condition. See the main text for more specific regulatory pathways.\
**Abbreviations:** G6Pase, glucose 6-phosphatase; GP, glycogen phosphorylase; PKA, protein kinase A.](dddt-12-121Fig4){#f4-dddt-12-121}

![Regulation of hepatic gluconeogenesis.\
**Notes:** In prolonged fasting, hepatic gluconeogenesis is initiated and catalyzed by a series of enzymes including PC, PEPCK, FBPase and G6Pase. With food intake, the hepatic glucose production pathways are inhibited by the activation of insulin-mediated PI3K/Akt pathway. CREB/TORC-2, HNFs, FoxO1 and a family of nuclear receptors are critical in the activation of hepatic glucose production. The solid black line represents for the pathway under fasting condition and the red dotted line for the feeding condition. See the main text for more specific regulatory pathways.\
**Abbreviations:** FBPase, fructose 1,6-bisphosphatase; FoxO1, forkhead box O1; G6Pase, glucose 6-phosphatase; HNF, hepatocyte nuclear factor; PC, pyruvate carboxylase; PEPCK, phosphoenolpyruvate carboxykinase; PI3K, phosphoinositide-3-kinase; PKA, protein kinase A; TORC-2, CREB and its co-activator 2.](dddt-12-121Fig5){#f5-dddt-12-121}

###### 

Major changes under metabolically disturbed state compared with normal state in the liver

  Hepatic glucose metabolism pathways      Major changes under metabolically disturbed state compared with normal state in the liver
  ---------------------------------------- -------------------------------------------------------------------------------------------
  Glucose uptake                           GLUT2 expression is downregulated
  GK translocation is decreased            
  Glycolysis                               Ratio of insulin and glucagon is reduced
  GK expression is reduced                 
  Glycogen synthesis                       GSK-3 is upregulated
  IRS-1/2 expression is reduced            
  Glycogenolysis and gluconeogenesis       GP activity is elevated
  G6Pase activity is increased             
  Transporters of G6Pase are upregulated   

**Abbreviations:** G6Pase, glucose 6-phosphatase; GK, glucokinase; GSK-3, glycogen synthase kinase 3; IRS-1, insulin receptor substrate 1.

###### 

Major targets and mechanisms of several antidiabetic multitarget natural products: quercetin, resveratrol, EGCG, curcumin and berberin

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound (mode of action in the liver)                                                     Molecular targets      Target tissue                              Refs
  ------------------------------------------------------------------------------------------ ---------------------- ------------------------------------------ ---------------------
  **Quercetin**\                                                                             α-glucosidases         Small intestine                            [@b95-dddt-12-121]
  (promoted hepatic glycolysis and glycogen synthesis)                                                                                                         

  GLUT2                                                                                      Small intestine        [@b96-dddt-12-121]                         

  Glucokinase                                                                                Liver                  [@b97-dddt-12-121]                         

  Glucose-6-phosphate                                                                        Liver                  [@b97-dddt-12-121]                         

  PI3K/Akt signaling                                                                         Liver                  [@b98-dddt-12-121]                         

  Glycogen synthase                                                                          Liver                  [@b99-dddt-12-121]                         

  AMPK/SIRT1 signaling                                                                       Adipose                [@b100-dddt-12-121]                        

  AMPK/GLUT4 signaling                                                                       Adipose/muscle         [@b99-dddt-12-121], [@b101-dddt-12-121]    

  Insulin receptor, PTP1B                                                                    Adipose                [@b102-dddt-12-121]                        

  TNF-α/PPAR-γ signaling                                                                     Adipose                [@b102-dddt-12-121]                        

  ERK1/2 signaling/insulin secretion                                                         Pancreas               [@b103-dddt-12-121]                        

  **Resveratrol**\                                                                           GLUT2                  Liver                                      [@b104-dddt-12-121]
  (promoted hepatic glucose uptake, suppressed hepatic glycogenolysis and gluconeogenesis)                                                                     

  SIRT1/PEPCK (G6Pase)                                                                       Liver                  [@b105-dddt-12-121]                        

  FoxO1/PEPCK (G6Pase)                                                                       Liver                  [@b105-dddt-12-121]                        

  FoxO1/glucokinase signaling                                                                Liver                  [@b106-dddt-12-121]                        

  HNF-4/glucokinase signaling                                                                Liver                  [@b106-dddt-12-121]                        

  AMPK/SIRT1 signaling                                                                       Liver/muscle/adipose   [@b107-dddt-12-121], [@b108-dddt-12-121]   

  AMPK/GLUT4 signaling                                                                       Muscle                 [@b107-dddt-12-121]                        

  PI3K/Akt signaling                                                                         Muscle                 [@b109-dddt-12-121]                        

  PGC-1α                                                                                     Adipose tissue         [@b110-dddt-12-121]                        

  **EGCG**\                                                                                  α-glucosidases         Small intestine                            [@b83-dddt-12-121]
  (promoted hepatic glycolysis, suppressed hepatic glycogenolysis and gluconeogenesis)                                                                         

  PEPCK, HNF-1, HNF-4                                                                        Small intestine        [@b111-dddt-12-121]                        

  Glycogen phosphorylase                                                                     Liver                  [@b83-dddt-12-121]                         

  LKB1/AMPK/IRS-1 signaling                                                                  Liver                  [@b112-dddt-12-121]                        

  PI3K/Akt/GSK-3β signaling                                                                  Liver                  [@b112-dddt-12-121]                        

  IRS-1/PEPCK signaling                                                                      Liver                  [@b113-dddt-12-121]                        

  IRS-1/G6Pase signaling                                                                     Liver                  [@b113-dddt-12-121]                        

  AMPK/GLUT4 signaling                                                                       Muscle/adipose         [@b114-dddt-12-121], [@b115-dddt-12-121]   

  PI3K/Akt/GLUT4 signaling                                                                   Muscle/adipose         [@b114-dddt-12-121], [@b115-dddt-12-121]   

  Glutamate dehydrogenase                                                                    Muscle/pancreas        [@b116-dddt-12-121]                        

  Inducible nitric oxide synthase                                                            Muscle/pancreas        [@b117-dddt-12-121], [@b118-dddt-12-121]   

  **Curcumin**\                                                                              α-amylase              Serum                                      [@b119-dddt-12-121]
  (suppressed hepatic glycogenolysis and gluconeogenesis)                                                                                                      

  GSK-3β                                                                                     Liver                  [@b120-dddt-12-121]                        

  AMPK/PEPCK (G6Pase) signaling                                                              Liver                  [@b121-dddt-12-121]                        

  PPAR-γ                                                                                     Liver/adipose          [@b122-dddt-12-121], [@b123-dddt-12-121]   

  AMPK/p-38 MAPK signaling                                                                   Muscle                 [@b124-dddt-12-121]                        

  AMPK/GLUT4 signaling                                                                       Muscle                 [@b125-dddt-12-121]                        

  **Berberin**\                                                                              PEPCK, G6Pase          Liver                                      [@b126-dddt-12-121]
  (suppressed hepatic glycogenolysis and gluconeogenesis)                                                                                                      

  FoxO1, SREBP1, ChREBP                                                                      Liver                  [@b126-dddt-12-121]                        

  PKC/IR signaling                                                                           Liver                  [@b93-dddt-12-121]                         

  PPAR-α/δ/λ                                                                                 Liver                  [@b91-dddt-12-121]                         

  AMPK/GLUT4 signaling                                                                       Muscle/adipose         [@b18-dddt-12-121]                         

  ERK/GLUT1 signaling                                                                        Adipose                [@b92-dddt-12-121]                         

  β cell regeneration                                                                        Pancreas               [@b127-dddt-12-121]                        

  Glucagon-like peptide-1 secretion                                                          Small intestine        [@b94-dddt-12-121]                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AMPK, AMP-activated protein kinase; ChREBP, carbohydrate response element binding protein; EGCG, epigallocatechin-3-gallate; FoxO1, forkhead box O1; G6Pase, glucose 6-phosphatase; GSK-3β, glycogen synthase kinase 3β; HNF-4, hepatocyte nuclear factor 4; IRS-1, insulin receptor substrate 1; PEPCK, phosphoenolpyruvate carboxykinase; PGC-1α, peroxisome proliferator-activated receptor gamma co-activator 1 alpha; PI3K, phosphoinositide-3-kinase; PPAR, peroxisome proliferator-activated receptor.
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